Results 1 to 10 of about 6,033 (178)
Renal Sympathetic Denervation for Hypertension. [PDF]
Kidney Int Rep, 2022 Arterial hypertension is the most prevalent global modifiable risk factor for cardiovascular morbidity and mortality. Despite the availability of numerous pharmacologic treatments, many patients do not achieve guideline-recommended blood pressure targets.
Guber K, Kirtane AJ.
europepmc +3 more sources
Exploring the relationship between ventricular fibrillation recurrence after defibrillation in myocardial infarction and the effectiveness of renal sympathetic denervation therapy [PDF]
BMC Cardiovascular DisordersObjective This study aimed to explore the association between electrophysiological markers of early recurrence after defibrillation in post-myocardial infarction ventricular fibrillation and the therapeutic effects of sympathetic renal denervation, as ...
Caixia Lin, Zhengyu Feng, Xiaowei Qiu
doaj +2 more sources
Renal sympathetic denervation for resistant hypertension: where do we stand after more than a decade [PDF]
Brazilian Journal of Nephrology, 2020 Despite the current availability of safe and efficient drugs for treating hypertension, a substantial number of patients are drug-resistant hypertensives.
Marco Antônio Peliky Fontes +3 more
doaj +3 more sources
Reconsidering Renal Sympathetic Denervation for Heart Failure. [PDF]
JACC Basic Transl Sci, 2017 [Figure: see text]
Tang WHW, Dunlap ME.
europepmc +4 more sources
Renal sympathetic denervation in patients with vasospastic angina. [PDF]
J Nucl Cardiol, 2020 Sympathetic overactivity has been linked to vasospastic angina (VSA), although the exact pathophysiology of VSA is poorly understood. The purpose of this study is to assess if renal sympathetic denervation (RDN) reduces cardiac sympathetic nerve activity with a subsequent beneficial effect on angina relief in patients with refractory VSA.Cardiac ...
Feyz L +5 more
europepmc +7 more sources
[The current state of renal sympathetic denervation in hypertension]. [PDF]
Arch Cardiol MexThis review provides an overview of the efficacy and safety of renal sympathetic denervation as a therapeutic approach for resistant hypertension. While the initial enthusiasm was sparked by the results of early clinical trials, it was dampened by the findings of the Symplicity HTN-3 study.
Gómez-Rosero JA +2 more
europepmc +3 more sources
Percutaneous renal sympathetic denervation in catecholaminergic polymorphic ventricular tachycardia [PDF]
Journal of Arrhythmia, 2017 Catheter-based renal sympathetic denervation may be an alternative after unsuccessful conventional ablation attempts.
Tolga Aksu, MD, Erdem Guler, MD
doaj +2 more sources
REC: Interventional Cardiology (English Ed.), 2022 Hypertension is the most prevalent cardiovascular risk factor. Despite pharmacological treatment, a high percentage of patients do not achieve an adequate blood pressure control.
Oriol Rodríguez-Leor +13 more
doaj +1 more source
Antioxidants, 2022 Oxidative stress and sustained sympathetic over-activity contribute to the pathogenesis of hypertension. Catheter-based renal denervation has been used as a strategy for treatment of resistant hypertension, which interrupts both afferent and efferent ...
Lu-Lu Wu +10 more
doaj +1 more source
Renal Sympathetic Denervation: Renal Function Concerns [PDF]
Hypertension, 2011 To the Editor: We have read the report of the Simplicity HTN-1 investigators on the 2-year durability of blood pressure reduction induced by catheter-based renal sympathetic denervation with great excitement1 because it represents a promising approach for treatment of resistant hypertension.2 However, several concerns arise that require clarification.
Konstantinos, Petidis +2 more
openaire +2 more sources